Do analysts prefer XBIT or HOWL?

Werewolf Therapeutics has a consensus price target of $3.75, indicating a potential upside of 884.25%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Werewolf Therapeutics is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Werewolf Therapeutics 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14

Is XBIT or HOWL more profitable?

XBiotech's return on equity of -26.10% beat Werewolf Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets XBiotech N/A -26.10% -25.06% Werewolf Therapeutics N/A -208.23% -75.12%

Does the media prefer XBIT or HOWL?

In the previous week, Werewolf Therapeutics had 9 more articles in the media than XBiotech. MarketBeat recorded 11 mentions for Werewolf Therapeutics and 2 mentions for XBiotech. XBiotech's average media sentiment score of 1.31 beat Werewolf Therapeutics' score of -0.15 indicating that XBiotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XBiotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Werewolf Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is HOWL or CYPH more profitable?

Cypherpunk Technologies' return on equity of -48.33% beat Werewolf Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Werewolf Therapeutics N/A -208.23% -75.12% Cypherpunk Technologies N/A -48.33% -42.21%

Do analysts recommend HOWL or BYSI?

Werewolf Therapeutics presently has a consensus price target of $3.75, indicating a potential upside of 884.25%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Werewolf Therapeutics is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Werewolf Therapeutics 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is HOWL or BYSI more profitable?

BeyondSpring's return on equity of 0.00% beat Werewolf Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Werewolf Therapeutics N/A -208.23% -75.12% BeyondSpring N/A N/A -14.00%

Is HOWL or GANX more profitable?

Gain Therapeutics' return on equity of -201.44% beat Werewolf Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Werewolf Therapeutics N/A -208.23% -75.12% Gain Therapeutics N/A -201.44% -136.24%

Does the media prefer HOWL or GANX?

In the previous week, Werewolf Therapeutics had 8 more articles in the media than Gain Therapeutics. MarketBeat recorded 11 mentions for Werewolf Therapeutics and 3 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 0.64 beat Werewolf Therapeutics' score of -0.15 indicating that Gain Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Werewolf Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Gain Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Werewolf Therapeutics (HOWL) Competitors

$0.38 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$0.40 +0.02 (+4.20%)

As of 06/12/2026 07:04 PM Eastern

Compare

HOWL vs. XBIT, CYPH, CLNN, BYSI, and GANX

Should you buy Werewolf Therapeutics stock or one of its competitors? MarketBeat compares Werewolf Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Werewolf Therapeutics include XBiotech (XBIT), Cypherpunk Technologies (CYPH), Clene (CLNN), BeyondSpring (BYSI), and Gain Therapeutics (GANX). These companies are all part of the "pharmaceutical products" industry.

How does Werewolf Therapeutics compare to XBiotech?

XBiotech (NASDAQ:XBIT) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

In the previous week, Werewolf Therapeutics had 9 more articles in the media than XBiotech. MarketBeat recorded 11 mentions for Werewolf Therapeutics and 2 mentions for XBiotech. XBiotech's average media sentiment score of 1.31 beat Werewolf Therapeutics' score of -0.15 indicating that XBiotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XBiotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Werewolf Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

XBiotech's return on equity of -26.10% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-26.10%	-25.06%
Werewolf Therapeutics	N/A	-208.23%	-75.12%

55.7% of XBiotech shares are owned by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are owned by institutional investors. 30.8% of XBiotech shares are owned by company insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

XBiotech has higher earnings, but lower revenue than Werewolf Therapeutics. XBiotech is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A
Werewolf Therapeutics	$1.88M	9.85	-$60.82M	-$1.24	N/A

XBiotech has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, Werewolf Therapeutics has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market.

Werewolf Therapeutics has a consensus price target of $3.75, indicating a potential upside of 884.25%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Werewolf Therapeutics is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Summary

Werewolf Therapeutics beats XBiotech on 8 of the 14 factors compared between the two stocks.

How does Werewolf Therapeutics compare to Cypherpunk Technologies?

Werewolf Therapeutics (NASDAQ:HOWL) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

Cypherpunk Technologies has lower revenue, but higher earnings than Werewolf Therapeutics. Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	$1.88M	9.85	-$60.82M	-$1.24	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A

Werewolf Therapeutics has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of -0.02, suggesting that its share price is 102% less volatile than the broader market.

64.8% of Werewolf Therapeutics shares are owned by institutional investors. Comparatively, 30.5% of Cypherpunk Technologies shares are owned by institutional investors. 23.6% of Werewolf Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Werewolf Therapeutics currently has a consensus price target of $3.75, indicating a potential upside of 884.25%. Given Werewolf Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Werewolf Therapeutics is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Werewolf Therapeutics had 10 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 11 mentions for Werewolf Therapeutics and 1 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 1.89 beat Werewolf Therapeutics' score of -0.15 indicating that Cypherpunk Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Werewolf Therapeutics	Neutral
Cypherpunk Technologies	Very Positive

Cypherpunk Technologies' return on equity of -48.33% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-208.23%	-75.12%
Cypherpunk Technologies	N/A	-48.33%	-42.21%

Summary

Werewolf Therapeutics beats Cypherpunk Technologies on 9 of the 14 factors compared between the two stocks.

How does Werewolf Therapeutics compare to Clene?

Werewolf Therapeutics (NASDAQ:HOWL) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

Werewolf Therapeutics has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market. Comparatively, Clene has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market.

Werewolf Therapeutics presently has a consensus price target of $3.75, indicating a potential upside of 884.25%. Clene has a consensus price target of $33.25, indicating a potential upside of 469.35%. Given Werewolf Therapeutics' higher probable upside, equities research analysts plainly believe Werewolf Therapeutics is more favorable than Clene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

64.8% of Werewolf Therapeutics shares are owned by institutional investors. Comparatively, 23.3% of Clene shares are owned by institutional investors. 23.6% of Werewolf Therapeutics shares are owned by insiders. Comparatively, 28.3% of Clene shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Werewolf Therapeutics has a net margin of 0.00% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-208.23%	-75.12%
Clene	-25,009.70%	N/A	-137.98%

In the previous week, Werewolf Therapeutics had 10 more articles in the media than Clene. MarketBeat recorded 11 mentions for Werewolf Therapeutics and 1 mentions for Clene. Clene's average media sentiment score of 1.89 beat Werewolf Therapeutics' score of -0.15 indicating that Clene is being referred to more favorably in the news media.

Company	Overall Sentiment
Werewolf Therapeutics	Neutral
Clene	Very Positive

Clene has lower revenue, but higher earnings than Werewolf Therapeutics. Clene is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	$1.88M	9.85	-$60.82M	-$1.24	N/A
Clene	$200K	373.18	-$26.17M	-$3.20	N/A

Summary

Werewolf Therapeutics and Clene tied by winning 8 of the 16 factors compared between the two stocks.

How does Werewolf Therapeutics compare to BeyondSpring?

Werewolf Therapeutics (NASDAQ:HOWL) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

In the previous week, Werewolf Therapeutics had 10 more articles in the media than BeyondSpring. MarketBeat recorded 11 mentions for Werewolf Therapeutics and 1 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 1.87 beat Werewolf Therapeutics' score of -0.15 indicating that BeyondSpring is being referred to more favorably in the news media.

Company	Overall Sentiment
Werewolf Therapeutics	Neutral
BeyondSpring	Very Positive

BeyondSpring has lower revenue, but higher earnings than Werewolf Therapeutics. BeyondSpring is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	$1.88M	9.85	-$60.82M	-$1.24	N/A
BeyondSpring	$1.75M	36.89	-$1.01M	-$0.14	N/A

64.8% of Werewolf Therapeutics shares are owned by institutional investors. Comparatively, 40.3% of BeyondSpring shares are owned by institutional investors. 23.6% of Werewolf Therapeutics shares are owned by insiders. Comparatively, 29.3% of BeyondSpring shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Werewolf Therapeutics presently has a consensus price target of $3.75, indicating a potential upside of 884.25%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Werewolf Therapeutics is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BeyondSpring's return on equity of 0.00% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-208.23%	-75.12%
BeyondSpring	N/A	N/A	-14.00%

Werewolf Therapeutics has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market.

Summary

BeyondSpring beats Werewolf Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Werewolf Therapeutics compare to Gain Therapeutics?

Werewolf Therapeutics (NASDAQ:HOWL) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

Gain Therapeutics has lower revenue, but higher earnings than Werewolf Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	$1.88M	9.85	-$60.82M	-$1.24	N/A
Gain Therapeutics	$50K	1,433.04	-$20.16M	-$0.58	N/A

Werewolf Therapeutics has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market.

Werewolf Therapeutics presently has a consensus price target of $3.75, suggesting a potential upside of 884.25%. Gain Therapeutics has a consensus price target of $8.50, suggesting a potential upside of 405.95%. Given Werewolf Therapeutics' higher probable upside, research analysts plainly believe Werewolf Therapeutics is more favorable than Gain Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Gain Therapeutics' return on equity of -201.44% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-208.23%	-75.12%
Gain Therapeutics	N/A	-201.44%	-136.24%

In the previous week, Werewolf Therapeutics had 8 more articles in the media than Gain Therapeutics. MarketBeat recorded 11 mentions for Werewolf Therapeutics and 3 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 0.64 beat Werewolf Therapeutics' score of -0.15 indicating that Gain Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Werewolf Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gain Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

64.8% of Werewolf Therapeutics shares are owned by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are owned by institutional investors. 23.6% of Werewolf Therapeutics shares are owned by insiders. Comparatively, 4.2% of Gain Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Werewolf Therapeutics beats Gain Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Werewolf Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HOWL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HOWL vs. The Competition

Export

Metric	Werewolf Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$18.52M	$3.39B	$6.52B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-0.31	20.00	24.00	24.42
Price / Sales	9.85	306.76	515.84	118.72
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	0.75	8.32	10.60	6.82
Net Income	-$60.82M	$23.94M	$3.57B	$337.56M
7 Day Performance	-0.24%	1.84%	0.59%	1.16%
1 Month Performance	-26.03%	-0.04%	1.54%	3.16%
1 Year Performance	-68.77%	44.82%	25.41%	30.60%

Werewolf Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HOWL Werewolf Therapeutics	3.2644 of 5 stars	$0.38 flat	$3.75 +884.3%	-68.8%	$18.52M	$1.88M	N/A	40	Gap Up
XBIT XBiotech	0.9484 of 5 stars	$2.37 flat	N/A	-11.4%	$72.26M	N/A	N/A	100
CYPH Cypherpunk Technologies	0.5921 of 5 stars	$0.68 -4.6%	N/A	+58.6%	$71.92M	N/A	N/A	40	Positive News Gap Up
CLNN Clene	3.9135 of 5 stars	$5.57 +4.5%	$33.25 +496.9%	+42.4%	$71.19M	$200K	N/A	100	Positive News Gap Down
BYSI BeyondSpring	0.2187 of 5 stars	$1.72 +1.2%	N/A	-43.7%	$70.73M	$1.75M	N/A	80	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HOWL) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Werewolf Therapeutics (HOWL) Competitors

HOWL vs. XBIT, CYPH, CLNN, BYSI, and GANX

How does Werewolf Therapeutics compare to XBiotech?

Summary

How does Werewolf Therapeutics compare to Cypherpunk Technologies?

Summary

How does Werewolf Therapeutics compare to Clene?

Summary

How does Werewolf Therapeutics compare to BeyondSpring?

Summary

How does Werewolf Therapeutics compare to Gain Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOWL vs. The Competition

Werewolf Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Werewolf Therapeutics (HOWL) Competitors

HOWL vs. XBIT, CYPH, CLNN, BYSI, and GANX

How does Werewolf Therapeutics compare to XBiotech?

Does the media prefer XBIT or HOWL?

Is XBIT or HOWL more profitable?

Do insiders and institutionals have more ownership in XBIT or HOWL?

Which has stronger valuation & earnings, XBIT or HOWL?

Which has more volatility & risk, XBIT or HOWL?

Do analysts prefer XBIT or HOWL?

Summary

How does Werewolf Therapeutics compare to Cypherpunk Technologies?

Which has better valuation and earnings, HOWL or CYPH?

Which has more risk and volatility, HOWL or CYPH?

Do institutionals & insiders have more ownership in HOWL or CYPH?

Do analysts prefer HOWL or CYPH?

Does the media favor HOWL or CYPH?

Is HOWL or CYPH more profitable?

Summary

How does Werewolf Therapeutics compare to Clene?

Which has more volatility and risk, HOWL or CLNN?

Do analysts rate HOWL or CLNN?

Do institutionals and insiders hold more shares of HOWL or CLNN?

Is HOWL or CLNN more profitable?

Does the media favor HOWL or CLNN?

Which has higher earnings and valuation, HOWL or CLNN?

Summary

How does Werewolf Therapeutics compare to BeyondSpring?

Does the media prefer HOWL or BYSI?

Which has higher valuation & earnings, HOWL or BYSI?

Do insiders and institutionals believe in HOWL or BYSI?

Do analysts recommend HOWL or BYSI?

Is HOWL or BYSI more profitable?

Which has more volatility and risk, HOWL or BYSI?

Summary

How does Werewolf Therapeutics compare to Gain Therapeutics?

Which has preferable earnings & valuation, HOWL or GANX?

Which has more volatility and risk, HOWL or GANX?

Do analysts prefer HOWL or GANX?

Is HOWL or GANX more profitable?

Does the media prefer HOWL or GANX?

Do institutionals & insiders hold more shares of HOWL or GANX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOWL vs. The Competition

Werewolf Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools